ACTA1 and breast carcinoma: Through ex vivo and in vivo assays, Shu et al. found increased expression of α-SMA, PDGFR-α, FAP, and TGF-β in C3a gene-treated CAFs, highlighting the C3aR gene as a potential therapeutic target to control tumor metastasis in breast cancer [145].